Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Veritas In Silico Inc. ( (JP:130A) ) is now available.
Veritas In Silico Inc. has announced it will book an extraordinary impairment loss of 135.52 million yen in the first quarter of the fiscal year ending December 2026, after reassessing the recoverability of tangible assets under Japanese GAAP. The write-down will lower quarterly business performance, but management expects subsequent revenues in the remainder of the year to offset the impact, leaving full-year earnings forecasts and the overall balance sheet largely unchanged.
The company indicated that the impairment will reduce the book value of its tangible and intangible assets, yet it anticipates only a limited effect on total assets and longer-term financial health. Veritas In Silico also signaled that it will continue to update investors if further disclosure items arise, underscoring its view that the loss is a contained accounting adjustment rather than a fundamental shift in strategy or operations.
More about Veritas In Silico Inc.
Veritas In Silico Inc., listed on the TSE Growth market under ticker 130A and headquartered in Tokyo, operates in the life sciences and biotechnology sector, focusing on computational and data-driven solutions for drug discovery and related applications. The company targets growth-stage investors and stakeholders interested in innovative, technology-enabled platforms that support pharmaceutical and biomedical research.
Average Trading Volume: 32,530
Technical Sentiment Signal: Sell
Current Market Cap: Yen3.01B
For detailed information about 130A stock, go to TipRanks’ Stock Analysis page.